Business Daily from THE HINDU group of publications
Tuesday, Jul 04, 2006

Cross Currency

Group Sites

Corporate - Standards & Benchmarks
Aurobindo gets tentative US nod for combo drug

Our Bureau

It said with the approval, several patients under PEPFAR would benefit.

Hyderabad , July 3

Aurobindo Pharma Ltd has announced that it has received the first tentative new drug application (NDA) approval from the United States Food and Drug Administration for fixed dose combination drug product containing lamivudine, zidovudine and nevirapine tablets (NDA) used in the treatment of HIV-1 infection.

In a press release here on Monday, APL said the three drugs were now available in a single tablet and it is the sole manufacturer of this approved combination.

This fixed dose combination pill comprising two-nucleoside reverse transcriptase inhibitors and a non-nucleoside reverse transcriptase inhibitors is used as first line therapy in most HIV patients. In most parts of the world, the regimen containing Lamivudine, Zidovudine and Nevirapine is very popular.

The company said with the approval , several patients under the US President's Emergency Programme for AIDS Relief would benefit.

According to Aurobindo Pharma, this is the first NDA generic approval in the world (innovator does not have this fixed dose combination) for a three-drug combination (amongst anti-retrovirals).

These drugs command $4.5-billion market worldwide and the usage is growing due to the commitment of the US Government in particular and the World Health Organisation to rehabilitate HIV patients. With this approval, the anti-retroviral product portfolio of the company has increased to 15 including two NDA approvals, the release said.

More Stories on : Standards & Benchmarks | Pharmaceuticals | Health

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Dr Reddy's launches new drug in urology segment

BHEL bags Rs 842-cr contracts in Rajasthan
L&T bags Rs 329-cr order from IOC, Bongaigaon
Hyderabad Ind starts production
Russian co EBC to enter thru 100 pc FDI route
Claris Lifesciences to set up units in China, Japan
Foreign acquisition
PM assures shares to NLC staff
Swaraj Mazda to sell Isuzu buses
No confirmation that pricing autonomy will be given: IOC
Rossell Tea plans foray into aviation sector
Aurobindo gets tentative US nod for combo drug
KSDP may be revived with Govt support
Fiat shifts cars from Kurla to Ranjangaon
Honda plans Rs 3,000-cr investment in India
Avon Organics turns around
Tata Steel's Q1 output up
Maruti June sales up 17.5%
Hyundai sales up 56% in June
Amrita Patel on Tata Tea board
Gujarat NRE MD to be on NZ coal company's board soon

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line